Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Zhaoke Ophthalmology Ltd. ( (HK:6622) ) has shared an announcement.
Zhaoke Ophthalmology Ltd. has entered a strategic partnership with TSH Biopharm to commercialize BRIMOCHOL™ PF in Taiwan. This partnership allows TSH Biopharm to register, import, and market the presbyopia-correcting eyedrop, potentially enhancing Zhaoke’s market presence in the Asia-Pacific region, where there is a significant unmet need for such therapeutics. The collaboration is expected to strengthen Zhaoke’s position in the ophthalmology market and provide a new solution for the widespread issue of presbyopia.
The most recent analyst rating on (HK:6622) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Zhaoke Ophthalmology Ltd. stock, see the HK:6622 Stock Forecast page.
More about Zhaoke Ophthalmology Ltd.
Zhaoke Ophthalmology Ltd. operates in the ophthalmology industry, focusing on developing and commercializing treatments for eye conditions. The company is involved in the clinical introduction and commercialization of innovative ophthalmic solutions, such as BRIMOCHOL™ PF, which targets presbyopia, a common age-related vision issue.
Average Trading Volume: 1,166,962
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.73B
See more insights into 6622 stock on TipRanks’ Stock Analysis page.